GSK
NEWS
It was another busy week for clinical trial announcement. Here’s a look.
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here’s what you need to know.
FDA says it is possible booster shots would be necessary for fully vaccinated individuals within a year even though vaccines are highly effective at COVID-19 prevention.
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
JOBS
IN THE PRESS